Moleculin Biotech Inc. (MBRX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Moleculin Biotech Inc. (MBRX:NASDAQ), powered by AI.

Current Price
$2.70
Sector
Healthcare
What is the Moleculin Biotech Inc. stock price forecast?

Moleculin Biotech Inc. is currently trading at $2.70. View real-time AI analysis on Alpha Lenz.

What is Moleculin Biotech Inc. insider trading activity?

View the latest insider trading data for Moleculin Biotech Inc. on Alpha Lenz.

What is Moleculin Biotech Inc.'s P/E ratio?

View Moleculin Biotech Inc.'s valuation metrics on Alpha Lenz.

Moleculin Biotech Inc.

NASDAQ · MBRX
$2.70-0.01(-0.37%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Moleculin Biotech Inc.'s future dividend policy...
Alpha Chat Insight

Moleculin Biotech Inc.'s ROE is -319.8%. Explore profitability and growth together.

Ask for details

Company Overview

Moleculin Biotech Inc. is a clinical-stage pharmaceutical company that primarily focuses on the development of oncology drug candidates. Based in Houston, Texas, the company concentrates its efforts on addressing unmet medical needs related to cancer. Moleculin Biotech is notable for its diverse pipeline of drug candidates, which includes small molecules targeting key biological pathways involved in cancer cell proliferation and survival. The company leverages its novel technologies, such as its Immune/Transcription Modulary Technology, to develop potential treatments that can be more effective and less toxic than existing therapies. Moleculin Biotech's research and developments are particularly influential within the biotechnology and pharmaceutical sectors, contributing to advancements in cancer treatment and offering hope for new therapeutic options. Through its innovative approach to drug development, Moleculin Biotech Inc. plays a significant role in the broader scientific and medical community, aiming to translate groundbreaking research into practical treatments that can improve patient outcomes.

CEOMr. Walter V. Klemp
SectorHealthcare
IndustryBiotechnology
Employees17

Company Statistics

FY 2025

Profile

N/AMarket Cap
$0.00Revenue
0.00Shares Out
17Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-171.88%ROA
-319.85%ROE
-128.57%ROIC

Financial Health

$8.88MCash & Cash Equivalents
$-1.76MNet Debt
47.45%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Moleculin Biotech Inc. (ticker: MBRX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 17 employees.

The current price is $2.7 with a P/E ratio of -x and P/B of -x.

ROE is -319.85%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Moleculin Biotech Inc. (MBRX) Stock Forecast 2026 $2.70 — Price, Financials & Analyst Targets | Alpha Lenz